SG162605A1 - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- SG162605A1 SG162605A1 SG200501782-7A SG2005017827A SG162605A1 SG 162605 A1 SG162605 A1 SG 162605A1 SG 2005017827 A SG2005017827 A SG 2005017827A SG 162605 A1 SG162605 A1 SG 162605A1
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- pharmaceutically acceptable
- valsartan
- bioavailable
- hydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59968700A | 2000-06-22 | 2000-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG162605A1 true SG162605A1 (en) | 2010-07-29 |
Family
ID=24400655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200501782-7A SG162605A1 (en) | 2000-06-22 | 2001-06-20 | Pharmaceutical compositions |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP2072049A3 (ko) |
JP (3) | JP2003535895A (ko) |
KR (2) | KR100525341B1 (ko) |
CN (2) | CN1221256C (ko) |
AU (2) | AU2001285768B2 (ko) |
BR (1) | BR0111868A (ko) |
CA (1) | CA2411882C (ko) |
CZ (1) | CZ20024180A3 (ko) |
EC (1) | ECSP024389A (ko) |
HK (2) | HK1052868A1 (ko) |
HU (1) | HUP0301390A3 (ko) |
IL (2) | IL153428A0 (ko) |
MX (1) | MXPA02012683A (ko) |
NO (1) | NO20026123L (ko) |
NZ (2) | NZ522953A (ko) |
PL (1) | PL358290A1 (ko) |
RU (1) | RU2333757C2 (ko) |
SG (1) | SG162605A1 (ko) |
SK (1) | SK18062002A3 (ko) |
WO (1) | WO2001097805A2 (ko) |
ZA (1) | ZA200210359B (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK9132001A3 (en) * | 1998-12-23 | 2002-01-07 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
ATE370732T1 (de) * | 2002-01-17 | 2007-09-15 | Novartis Pharma Gmbh | Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
TWI299663B (en) * | 2002-05-14 | 2008-08-11 | Novartis Ag | Methods of treatment |
JP4505859B2 (ja) * | 2003-08-08 | 2010-07-21 | 味の素株式会社 | ナテグリニド含有製剤 |
WO2006021443A2 (en) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
EA015108B1 (ru) | 2004-12-24 | 2011-06-30 | КРКА, д.д., НОВО МЕСТО | Способ получения твердой фармацевтической композиции, содержащей валсартан |
JP2009001520A (ja) * | 2007-06-21 | 2009-01-08 | Kowa Co | ジフェンヒドラミン含有固形製剤 |
CA2701695A1 (en) | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
WO2009059605A1 (en) * | 2007-11-08 | 2009-05-14 | University Of Copenhagen | Small scale solid state screening |
EP2067470A1 (en) * | 2007-12-03 | 2009-06-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions containing valsartan and process for its preparation |
WO2011102702A2 (en) | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
CN102362865B (zh) * | 2011-10-28 | 2013-06-26 | 山东司邦得制药有限公司 | 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用 |
WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
CN103599084B (zh) * | 2013-11-22 | 2018-10-30 | 威海迪素制药有限公司 | 一种降压组合物 |
CN112807286A (zh) * | 2021-01-20 | 2021-05-18 | 海南皇隆制药股份有限公司 | 一种缬沙坦分散片制备方法和缬沙坦分散片 |
CN112826806A (zh) * | 2021-01-20 | 2021-05-25 | 海南皇隆制药股份有限公司 | 一种缬沙坦片制备方法和缬沙坦片 |
EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049394A2 (en) * | 1996-06-27 | 1997-12-31 | Novartis Ag | Sold oral dosage forms of valsartan |
WO2000038676A1 (en) * | 1998-12-23 | 2000-07-06 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
WO2001076573A2 (en) * | 2000-04-12 | 2001-10-18 | Novartis Ag | Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0443983T3 (da) | 1990-02-19 | 1996-03-18 | Ciba Geigy Ag | Acrylforbindelser |
CA2184712A1 (en) | 1994-03-17 | 1995-09-21 | Marc De Gasparo | Treatment of diabetic nephropathy with valsartan |
JPH11513395A (ja) * | 1995-10-06 | 1999-11-16 | ノバルティス・アクチエンゲゼルシャフト | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
JP4369994B2 (ja) * | 1996-02-29 | 2009-11-25 | ノバルティス アクチエンゲゼルシャフト | アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト |
CA2240161C (en) * | 1996-05-20 | 2005-05-24 | Janssen Pharmaceutica N.V. | Antifungal compositions with improved bioavailability |
US6362371B1 (en) * | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
-
2001
- 2001-06-20 SK SK1806-2002A patent/SK18062002A3/sk unknown
- 2001-06-20 SG SG200501782-7A patent/SG162605A1/en unknown
- 2001-06-20 KR KR10-2002-7017469A patent/KR100525341B1/ko not_active IP Right Cessation
- 2001-06-20 PL PL01358290A patent/PL358290A1/xx not_active Application Discontinuation
- 2001-06-20 WO PCT/EP2001/006983 patent/WO2001097805A2/en active Search and Examination
- 2001-06-20 HU HU0301390A patent/HUP0301390A3/hu not_active Application Discontinuation
- 2001-06-20 KR KR1020057013346A patent/KR100659644B1/ko not_active IP Right Cessation
- 2001-06-20 CZ CZ20024180A patent/CZ20024180A3/cs unknown
- 2001-06-20 RU RU2003100507/15A patent/RU2333757C2/ru not_active IP Right Cessation
- 2001-06-20 NZ NZ522953A patent/NZ522953A/en not_active IP Right Cessation
- 2001-06-20 CN CNB018115527A patent/CN1221256C/zh not_active Expired - Fee Related
- 2001-06-20 MX MXPA02012683A patent/MXPA02012683A/es active IP Right Grant
- 2001-06-20 EP EP09004205A patent/EP2072049A3/en not_active Withdrawn
- 2001-06-20 JP JP2002503289A patent/JP2003535895A/ja not_active Withdrawn
- 2001-06-20 EP EP01965014A patent/EP1296677A2/en not_active Ceased
- 2001-06-20 IL IL15342801A patent/IL153428A0/xx unknown
- 2001-06-20 CA CA2411882A patent/CA2411882C/en not_active Expired - Fee Related
- 2001-06-20 AU AU2001285768A patent/AU2001285768B2/en not_active Ceased
- 2001-06-20 NZ NZ540748A patent/NZ540748A/en not_active IP Right Cessation
- 2001-06-20 CN CNB2005100510503A patent/CN100450478C/zh not_active Expired - Fee Related
- 2001-06-20 BR BR0111868-4A patent/BR0111868A/pt not_active Application Discontinuation
- 2001-06-20 AU AU8576801A patent/AU8576801A/xx active Pending
-
2002
- 2002-12-12 IL IL153428A patent/IL153428A/en not_active IP Right Cessation
- 2002-12-12 EC EC2002004389A patent/ECSP024389A/es unknown
- 2002-12-19 NO NO20026123A patent/NO20026123L/no unknown
- 2002-12-20 ZA ZA200210359A patent/ZA200210359B/xx unknown
-
2003
- 2003-07-08 HK HK03104842.9A patent/HK1052868A1/zh unknown
-
2006
- 2006-03-20 HK HK06103477.0A patent/HK1083452A1/xx unknown
-
2007
- 2007-01-11 JP JP2007003546A patent/JP2007091758A/ja not_active Withdrawn
-
2012
- 2012-08-02 JP JP2012172246A patent/JP2012211200A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049394A2 (en) * | 1996-06-27 | 1997-12-31 | Novartis Ag | Sold oral dosage forms of valsartan |
WO2000038676A1 (en) * | 1998-12-23 | 2000-07-06 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
WO2001076573A2 (en) * | 2000-04-12 | 2001-10-18 | Novartis Ag | Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG162605A1 (en) | Pharmaceutical compositions | |
CA2378469A1 (en) | An oral solid composition comprising carbidopa, levodopa and entacapone | |
CA2427815A1 (en) | Controlled release hydrocodone formulations | |
HUP0302086A2 (hu) | Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására | |
CA2339991A1 (en) | Microemulsions as solid dosage forms for oral administration | |
WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
HUP0302319A3 (en) | Pharmaceutical composition for oral administration of active ingredient | |
IL150696A0 (en) | Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof | |
AU2001263229A1 (en) | Compositions and methods for administration of pharmacologically active compounds | |
WO2001042219A3 (en) | Novel substituted phenanthridinones and methods of use thereof | |
PL342988A1 (en) | Novel galenic formulations of meloxicam for oral administration | |
GEP20063882B (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
DE69413237D1 (en) | Plättchenaggregationsinhibitoren | |
PL333524A1 (en) | Improved prolonged release pharmaceutic preparation for administration of nephadosone, oral dosage form thereof and improved nephadosone administration method | |
BG105436A (en) | Pharmaceutical compositions comprising entacapone or nitecapone as well as a cross-linked cellulpse derivative | |
PL348419A1 (en) | Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
HUP0204080A3 (en) | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them | |
HU9600758D0 (en) | Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption | |
WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
HUP0105426A3 (en) | Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems and pharmaceutical compositions thereof | |
CA2376847A1 (en) | Complex of eletriptan and a cyclodextrin derivative | |
WO2002011740A3 (en) | 'slow release' pharmaceutical compositions comprising lithium carbonate | |
WO2000064427A3 (en) | Lamivudine containing pharmaceutical formulation | |
HUP0401912A3 (en) | Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them |